Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Francesca Palandri: Dynamic, Treatment Response-Driven Risk Assessment in Polycythemia Vera
Francesca Palandri/LinkedIn
Jul 4, 2026, 17:25

Francesca Palandri: Dynamic, Treatment Response-Driven Risk Assessment in Polycythemia Vera

Francesca Palandri, Hematologist at Sant’Orsola-Malpighi Polyclinic – Bologna University Hospital, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Blood Advances, adding:

“It’s time to move from static risk assessment to a dynamic, treatment-response-driven approach in Polycythemia Vera.

A new Italian multicenter study coordinated by IRCCS Sant’Orsola Polyclinic – Bologna University Hospital introduces PV-RR6 — a new dynamic prognostic model integrating three readily available variables assessed within the first 6 months of therapy:

  • Ruxolitinib dose less than 10 mg BID
  • Failure to achieve at least a 50% spleen length reduction
  • Persistent phlebotomy requirement

The model identifies three risk categories with clearly distinct 5-year EFS: 89% (low), 71% (intermediate), and 39% (high risk).

Ruxolitinib underdosing (less than 10 mg BID) emerged as an independent prognostic factor for worse event-free survival.

  • Underdosing at one timepoint – nearly 2 times higher risk of adverse events (HR 1.94)
  • Underdosing at every timepoint – over 5 times higher risk (HR 5.63)
  • The most common trigger was mild anemia (Hb 10–12) – for which the label does NOT recommend dose reduction.

Takeaway: In PV, as in myelofibrosis, underdosing isn’t conservative — it’s a risk factor.

PV-RR6 flags high-risk patients early enough to act: optimize dose, switch, or consider clinical trials.

Try the calculator.”

Title: A dynamic prognostic model for Polycythemia Vera long-terms outcomes in patients treated with Ruxolitinib

Authors: Francesca Palandri, Alessandra Dedola, Giovanni Caocci, Elena Rossi, Elena Maria Elli, Chiara SartorCorresponding Author, Roberto Latagliata, Novella Pugliese, Erika Morsia, Gianni Binotto, Francesco Mendicino, Alessia Tieghi, Giulia Benevolo, Bruno Martino, Alessandra D’Addio, Mario Tiribelli, Daniela Cilloni, Monica Crugnola, Fabrizio Cavalca, Emilia Scalzulli, Francesco Lanza, Fabrizio Pane, Giuseppe A Palumbo, Florian H Heidel, Valerio De Stefano, Massimo Breccia, Filippo Branzanti

Francesca Palandri

Stay updated on all scientific advances with Hemostasis Today.

Alessandra D'Addio Alessandra Dedola Alessia Tieghi Blood Bruno Martino Chiara SartorCorresponding Author Daniela Cilloni Elena Maria Elli Elena Rossi Emilia Scalzulli Erika Morsia Fabrizio Cavalca Fabrizio Pane Filippo Branzanti Florian H Heidel Francesca Palandri Francesco Lanza Francesco Mendicino Gianni Binotto Giovanni Caocci Giulia Benevolo Giuseppe A Palumbo Health Hematology Hemostasis News Hemostasis Today Mario Tiribelli Massimo Breccia Medicine Monica Crugnola myelofibrosis Novella Pugliese polycythemia vera PV PV-RR6 Roberto Latagliata ruxolitinib Valerio De Stefano
NewsFeed